BELFAST-based heart health technology company B-Secur has launched the latest evolution of its innovative HeartKey technology in a significant scale-up of global operations to target the multi-billion dollar consumer and healthcare markets.
The company, which has doubled its workforce in recent months to more than 75 employees and counts consumer technology brands as well as the world’s leading semiconductor manufacturers among its customers, has launched its new technology based on the cloud, HeartKey 2.0 in San Francisco last weekend.
FDA-approved software suite reduces cardiac tracing signal noise, elevating electrocardiogram (ECG) interpretation to new heights of efficiency and accuracy for clinicians and facilitating the growing trend toward greater remote heart monitoring through wearable devices
HeartKey 2.0, which also offers a range of health diagnostic algorithms, was unveiled Friday at the Heart Rhythm Expo, a cardiac medical conference attended by leading clinicians, scientists, researchers and innovators.
B-Secur Managing Director Alan Foreman said, “In 2021, we raised $12 million with the firm intention of accelerating our business expansion in the United States.
“The launch of HeartKey 2.0 is an integral part of our expansion plans. Cloud-based technology helps position us strategically at the center of the converging multi-billion dollar consumer and medical device industries.
“B-Secur is going from strength to strength, we now employ over 75 highly skilled people, the majority of whom are based at our Belfast headquarters.
“We continue in expansion mode and have invested heavily in a new brand and website that will continue to make us attractive partners for the biggest tech companies on the planet.
“We are proud to have achieved all of this from our home in Belfast and we are already working on exciting new projects that will allow us to continue to be rooted in this city.”
The latest HeartKey 2.0 technology refines and improves signal clarity, enabling ECG clinicians to make a faster, more accurate diagnosis, accelerating the clinical pathway and saving more lives.